Mushroom Lion’s Mane / Dose Cancer Research Results

mushLions, Mushroom Lion’s Mane: Click to Expand ⟱
Features:

Lion’s Mane mushroom (Hericium erinaceus; “HE”; culinary + medicinal mushroom). Key bioactives include erinacines (notably erinacine A; typically mycelium-derived) and hericenones (often fruiting-body-associated), plus polysaccharides (β-glucans).

Primary mechanisms (conceptual rank):
1) ↑ Neurotrophic signaling (NGF/BDNF-related; CREB/neurite outgrowth)
2) ↓ Neuroinflammation (e.g., NF-κB/cytokine tone; microglial activation models)
3) ↑ Antioxidant/stress-defense (often ↑ NRF2; ↓ ROS burden; mitochondrial protection)

Bioavailability / PK relevance: activity depends strongly on extract type (mycelium vs fruiting body; erinacine-standardized vs not). Some erinacines are reported to be BBB-permeable in the literature; human PK is not well-characterized for most commercial products.

In-vitro vs oral exposure: many anti-cancer / signaling findings use extract concentrations likely above achievable systemic levels from typical supplements (qualifier: high concentration only unless otherwise demonstrated in vivo).

Clinical evidence status: small human trials/pilot RCTs for cognition/early AD/MCI and healthy adults (signals but limited); cancer evidence remains largely preclinical/adjunct-hypothesis.

Lion’s Mane Mushroom (Hericium erinaceus) is renowned for its potential health benefits, particularly in areas like neuroprotection, cognitive function, and immune support.

-Most commonly cited mechanisms of Lion’s Mane is its ability to stimulate the synthesis of Nerve Growth Factor (NGF)
-Specific compounds such as hericenones and erinacines present in the mushroom are thought to be responsible for this effect.
-May inhibit NF-κB Pathway
-May lower the production of pro-inflammatory cytokines (e.g., TNF-α, IL-6)
-Neutralize free radicals, reducing oxidative stress
-Lion’s Mane influences gut health and, in turn, the gut-brain axis
-Anti-inflammatory responses, antioxidant protection

-Mushrooms, including Lion’s Mane (Hericium erinaceus), contain ergosterol—a precursor to vitamin D. When exposed to ultraviolet (UV) light (such as sunlight), ergosterol is converted to vitamin D₂ (ergocalciferol).

Lion’s Mane (Hericium erinaceus) — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 PI3K/AKT survival signaling ↓ ↔ (context-dependent) R/G Pro-apoptotic shift; reduced proliferative signaling Reported suppression of PI3K/AKT in cancer models; often paired with apoptosis readouts (model- & extract-dependent).
2 RAS/MAPK (ERK) proliferative signaling ↓ ↔ (context-dependent) R/G Growth inhibition / reduced mitogenic drive Observed in some cancer cell studies alongside reduced viability; dose/time dependence common.
3 Intrinsic apoptosis (mitochondrial; caspases) ↑ ↔ / ↑ (cytoprotection; model-dependent) R/G Cancer cell death / chemosensitization hypothesis Frequently reported outcome in vitro; translation depends on achievable exposure and tumor selectivity.
4 NF-κB / inflammatory cytokine programs ↓ (context-dependent) ↓ R/G Anti-inflammatory / anti-survival signaling Anti-inflammatory effects are central in neuro models; in tumors may reduce pro-survival inflammation but can be tumor-type specific.
5 ROS / redox stress balance ↑ or ↓ (dose-dependent) ↓ P/R Redox modulation (pro-oxidant cytotoxicity vs antioxidant protection) Normal cells: commonly described as antioxidant/mitochondrial-protective. Cancer cells: extracts can act cytotoxically at higher concentrations (biphasic behavior).
6 NRF2 axis (stress-defense / resistance) ↔ / ↑ (context-dependent) ↑ R/G Stress-response activation Normal cells: ↑ NRF2 generally cytoprotective. Cancer: ↑ NRF2 can be double-edged (possible therapy resistance in some contexts).
7 Cell cycle control (checkpoint enforcement) ↓ proliferation ↔ G Cell-cycle arrest phenotype Common downstream phenotype in preclinical cancer studies; specifics vary by line/extract.
8 Migration / invasion (EMT, MMP-related) ↓ (model-dependent) ↔ G Anti-metastatic phenotype hypothesis Reported in some preclinical literature; often requires sustained exposure.
9 Angiogenesis programs (e.g., VEGF/HIF-1α coupling) ↓ (model-dependent) ↔ G Anti-angiogenic hypothesis Evidence is less consistent; often indirect via inflammation/redox signaling.
10 Ca²⁺ handling / ER–mitochondria stress coupling ↔ (model-dependent) ↔ (model-dependent) P/R Stress signaling modulation Not a universal primary axis; consider when apoptosis/UPR/mitochondrial stress is a defined readout in a given model.
11 Ferroptosis (iron/lipid peroxidation) ↔ (insufficiently established) ↔ R/G Not a dominant canonical mechanism May become relevant only in specific redox/iron contexts; not consistently central in HE literature.
12 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) — Exposure + standardization limitations Major constraint: product heterogeneity (mycelium vs fruiting body; erinacine-standardized vs not), limited human PK, and many in-vitro doses likely supra-physiologic.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr


AD relevance: Lion’s Mane (Hericium erinaceus; especially erinacine-A–enriched mycelium preparations) is primarily studied as a neurotrophic + neuroprotective dietary intervention with small human trials/pilot RCTs in early AD/MCI and related cognitive outcomes.

Primary mechanisms (conceptual rank):
1) ↑ Neurotrophic signaling (↑ NGF/BDNF-related pathways; CREB/neurite outgrowth)
2) ↓ Neuroinflammation (↓ NF-κB/cytokines in models; microglial tone)
3) ↑ Stress-defense & mitochondrial resilience (often ↑ NRF2; ↓ ROS burden)

Bioavailability / PK relevance: effects depend on standardized preparations (erinacine A content; dosing regimen). Evidence base includes a ~49-week pilot double-blind placebo-controlled study of erinacine-A–enriched mycelium; overall evidence remains limited by sample sizes and product variability.

Clinical evidence status: small human trials/pilot RCTs (signals but not definitive; adjunct/early evidence).

Lion’s Mane (Hericium erinaceus) — AD/Neurodegeneration Pathway Map

Rank Pathway / Axis Cells TSF Primary Effect Notes / Interpretation
1 Neurotrophins (NGF/BDNF-related; CREB/neuritogenesis) ↑ G Synaptic support / plasticity, neurite outgrowth Core proposed mechanism; often linked to erinacines/hericenones and downstream neurogenesis/survival signaling in models.
2 Neuroinflammation (NF-κB, cytokine tone; microglial activation models) ↓ R/G Reduced inflammatory stress on neurons Anti-inflammatory signaling is commonly invoked as neuroprotective; timing can be acute (signaling) → chronic (phenotype).
3 ROS / oxidative stress burden ↓ P/R Lower oxidative damage pressure Often paired with mitochondrial protection claims; may be secondary to NRF2 activation.
4 NRF2 antioxidant-response program ↑ R/G Stress-defense upshift Generally aligned with neuroprotection; interpret alongside redox context and dosing/extract standardization.
5 Mitochondrial function / bioenergetics resilience ↑ R/G Improved cellular resilience under stress Often described downstream of reduced ROS/inflammation; phenotype-level outcomes require sustained exposure.
6 Aβ / tau-associated pathology (amyloid/tau cascades) ↓ (model-dependent) G Reduced pathological burden (preclinical emphasis) Evidence is stronger preclinically than clinically; treat as supportive/secondary unless specific human biomarker replication exists.
7 Ca²⁺ homeostasis / excitotoxic vulnerability ↔ (context-dependent) P/R Excitotoxic stress modulation (hypothesis) Include when models explicitly measure Ca²⁺/ER stress/UPR; not always primary in HE clinical framing.
8 Clinical Translation Constraint ↓ (constraint) — Evidence + standardization limitations Small trials/pilot RCTs; product heterogeneity (erinacine content; mycelium vs fruiting body) and limited human PK constrain inference.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
Dose, Dosage: Click to Expand ⟱
Source:
Type:
Drug dosage vs efficacy, and actual dosage number of research papers.
Scientific Papers found: Click to Expand⟱
2484- mushLions,    Neurotrophic and Neuroprotective Effects of Hericium erinaceus
- Review, Stroke, NA - Review, AD, NA - Review, Park, NA
*eff↑, *BBB↑, *Dose↝, *neuroP↑, *cognitive↑, *toxicity∅,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Barriers & Transport ⓘ

BBB↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   eff↑, 1,  

Functional Outcomes ⓘ

cognitive↑, 1,   neuroP↑, 1,   toxicity∅, 1,  
Total Targets: 6

Scientific Paper Hit Count for: Dose, Dosage
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:325  Target#:1114  State#:%  Dir#:4
  wNotes=0  sortOrder:rid,rpid

 

Home Page